Kibur Medical

Executive Summary

Kibur Medical is a San Diego-based biotechnology company founded in 2018, focused on transforming cancer care through its innovative NanoNail™ implantable microdevice. This device enables in situ, high-throughput pharmaco-phenotyping of tumors by simultaneously testing up to 20 different drugs or combinations. The technology aims to close the translational gap in oncology drug development by providing deep molecular insights into tumor response, thereby accelerating lead discovery and improving clinical success rates. Kibur Medical has received regulatory approval, positioning it to commercialize this novel platform and fundamentally enhance personalized cancer therapy. The company's platform addresses a critical unmet need in oncology: the slow and inefficient process of drug testing. By enabling rapid, multi-drug testing within the tumor microenvironment, NanoNail™ can significantly reduce the time and cost of drug development while increasing the likelihood of clinical success. With its approved status, Kibur Medical is poised to partner with pharmaceutical companies and academic institutions to drive adoption. The potential impact on precision oncology is substantial, offering a pathway to more effective combination therapies and improved patient outcomes. As it moves toward commercial deployment, Kibur Medical represents a compelling opportunity in the drug delivery and diagnostics space.

Upcoming Catalysts (preview)

• Q3 2026First Commercial Deployment of NanoNail™ in Clinical Setting80% success
• Q4 2026Strategic Partnership with Major Pharmaceutical Company65% success
• Q2 2026Publication of Clinical Validation Data in Peer-Reviewed Journal75% success